According to the research report titled ‘GLOBAL Precision Medicine Market 2021-2028’, available with Market Study Report, global precision medicine market is anticipated to register 9.79% CAGR over the forecast duration 2021-2028.
 

Surging geriatric patients suffering from chronic diseases is the primary growth catalyst for worldwide precision medicine industry. Factors like digital collaboration among organizations and research groups, coupled with studies for recognition of genetic makeup in human genome are also propelling the market growth.

 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3552233/

 

Moreover, investments by government and private players for cancer treatment innovations, technological advancements leading to cognizance of personal health as well as demand for preventive care are further augmenting the industry outlook.

 

On the contrary, alterations in reimbursement and regularity processes, strict drug approval methods, and security threats pertaining to data sharing are factors impeding the growth of global precision medicine market.

 

Based on application scope, the industry is classified into infectious diseases, gastroenterology, cardiovascular, oncology, lifestyle & endocrinology, neurology/physiatry, and others. In terms of component, the marketspace is bifurcated into precision therapeutics, applied science, digital health & information technology, and precision diagnostics.
 

Moving on to regional landscape, the business intelligence report includes the latest prospects across North America, Middle East & Africa, Asia Pacific, Europe, and Latin America.
 

As per estimates, Asia Pacific precision medicine industry share is expected to bolster at a momentous growth rate in the stipulated timeframe, owing to introduction of novel treatments, increasing healthcare awareness as well as advanced human genome libraries that help scientists in research to produce ethnicity-specific sequences. Moreover, diseases leading to adoption of sequencing technologies propelling genome mapping programs further boost the growth of the regional market.
 

The competitive landscape of worldwide precision medicine industry is defined by companies such as QIAGEN N.V., Bio-Rad Laboratories Inc., Pfizer Inc., Eli Lilly and Company, Danaher Corporation, Thermo Fisher Scientific, Novartis International AG, Eagle Genomics Ltd., NanoString Technologies Inc., Quest Diagnostics, Abbott Laboratories, F. Hoffmann-La Roche AG, Laboratory Corporation of America Holdings, Biocrates Life Sciences AG, AstraZeneca plc, and Intomics A/S among others.